CoChat

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review

Open access
Santarpia, Mariacarmela, Ciappina, Giuliana, Spagnolo, Calogera Claudia, Squeri, Andrea, Passalacqua, Maria Ilenia, Aguilar, Andrés, Gonzalez-Cao, Maria, Giovannetti, Elisa, Silvestris, Nicola, Rosell, Rafael · 2023 · Translational Lung Cancer Research

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Abstract

Background and Objective: Non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma viral oncogene homolog (KRAS) driver alterations harbors a poor prognosis with standard therapies, including chemotherapy and/or immunotherapy with anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) antibodies. Selective KRAS G12C inhibitors have been shown to provide significant clinical benefit in pretreated NSCLC patients with KRAS G12C mutation. Methods: In this review, we describe KRAS and the biology of KRAS-mutant tumors and review data from preclinical studies and clinical trials on KRAS-targeted therapies in NSCLC patients with KRAS G12C mutation. Key Content and Findings: KRAS is the most frequently mutated oncogene in human cancer. The G12C is the most common KRAS mutation found in NSCLC. Sotorasib is the first, selective KRAS G12C inhibitor to receive approval based on demonstration of significant clinical benefit and tolerable safety profile in previously treated, KRAS G12C-mutated NSCLC. Adagrasib, a highly selective covalent inhibitor of KRAS G12C, has also shown efficacy in pretreated patients and other novel KRAS inhibitors are being under evaluation in early-phase studies. Similarly to other oncogene-directed therapies, mechanisms of intrinsic and acquired resistance limiting the activity of these agents have been described. Conclusions: The discovery of selective KRAS G12C inhibitors has changed the therapeutic scenario of KRAS G12C-mutant NSCLC. Various studies testing KRAS inhibitors in different settings of disease, as single-agent or in combination with targeted agents for synthetic lethality and immunotherapy, are currently ongoing in this molecularly-defined subgroup of patients to further improve clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/tlcr-22-639

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The KRAS pathway. In basal conditions, KRAS binds to the GDP and remains in a state of inactivity. When extracellular growth factors transmit signals to the receptor tyrosine kinases, SOS interacts with the KRAS-GDP complex leading to GDP release and GTP replacement. The binding of GTP and KRAS induces structural changes leading to the activation of KRAS. Conversely, GAP enhances the intrinsic activity of GTPase in KRAS to preserve the reaction in which GTP is hydrolyzed into GDP. The KRAS cycle between activated and inactivated state functions as a strong molecular switching cycle that controls multiple signaling cascades, including the RAF-MEK-ERK pathway, PI3K-AKT-mTOR pathway and other signaling pathways regulating cell proliferation, differentiation and survival. Created with https://biorender.com/. GDP, guanosine diphosphate; KRAS, Kirsten rat sarcoma viral oncogene; GAP, GTPase-activating protein; GTPase, guanosine triphosphate hydrolase; GTP, guanosine triphosphate; GEF, guanine exchange factor; RALGDS, ral guanine nucleotide dissociation stimulator; RAL, ras-like protooncogene; PLD, phospholipase D2; RAC, ribosome-associated complex; TBK1, TANK-binding kinase 1; CDC42, cell division control protein 42 homolog; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor κB; RAF, rapidly accelerated fibrosarcoma; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; TIAM1, T-cell lymphoma invasion and metastasis-inducing protein 1; SOS, son of sevenless.
Figure 1 The KRAS pathway. In basal conditions, KRAS binds to the GDP and remains in a state of inactivity. When extracellular growth factors transmit signals to the receptor tyrosine kinases, SOS interacts with the KRAS-GDP complex leading to GDP release and GTP replacement. The binding of GTP and KRAS induces structural changes leading to the activation of KRAS. Conversely, GAP enhances the intrinsic activity of GTPase in KRAS to preserve the reaction in which GTP is hydrolyzed into GDP. The KRAS cycle between activated and inactivated state functions as a strong molecular switching cycle that controls multiple signaling cascades, including the RAF-MEK-ERK pathway, PI3K-AKT-mTOR pathway and other signaling pathways regulating cell proliferation, differentiation and survival. Created with https://biorender.com/. GDP, guanosine diphosphate; KRAS, Kirsten rat sarcoma viral oncogene; GAP, GTPase-activating protein; GTPase, guanosine triphosphate hydrolase; GTP, guanosine triphosphate; GEF, guanine exchange factor; RALGDS, ral guanine nucleotide dissociation stimulator; RAL, ras-like protooncogene; PLD, phospholipase D2; RAC, ribosome-associated complex; TBK1, TANK-binding kinase 1; CDC42, cell division control protein 42 homolog; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor κB; RAF, rapidly accelerated fibrosarcoma; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; TIAM1, T-cell lymphoma invasion and metastasis-inducing protein 1; SOS, son of sevenless.CC BY-NC-ND · PubMed Central
Figure 2 Kaplan-Meier PFS analysis. Comparison of the PFS between K-only, KP and KS, indicating lower survival in patients with concomitant KRAS and STK11 mutations (*P=0.05 for KS vs. K-only). In addition, higher VAF tends to correlate with lower PFS. PFS, progression-free survival; KRAS, Kirsten rat sarcoma viral oncogene; KP, KRAS + TP53 mutations; KS, KRAS + STK11 mutations; CI, confidence interval; VAF, variant allele frequency; EOS, end of study (disease progression); STK11, serine/threonine kinase 11; TP53, tumor protein p53.
Figure 2 Kaplan-Meier PFS analysis. Comparison of the PFS between K-only, KP and KS, indicating lower survival in patients with concomitant KRAS and STK11 mutations (*P=0.05 for KS vs. K-only). In addition, higher VAF tends to correlate with lower PFS. PFS, progression-free survival; KRAS, Kirsten rat sarcoma viral oncogene; KP, KRAS + TP53 mutations; KS, KRAS + STK11 mutations; CI, confidence interval; VAF, variant allele frequency; EOS, end of study (disease progression); STK11, serine/threonine kinase 11; TP53, tumor protein p53.CC BY-NC-ND · PubMed Central
Figure 3 Novel therapeutic strategies for KRAS-mutant resistant to KRAS G12C inhibitors. Mechanisms of resistance to KRAS G12C inhibitors include compensatory activation of RTKs such as ERBB2/3, FGFR1, AXL and MET. This can lead to SHP2 phosphorylation, which is required for ERK activation through RAS modulation. Another mechanism can be the EMT. The onset of these resistance mechanisms leads to the development of alternative therapeutic strategies. The figure highlights the possibility of combine drugs active on different levels of the cellular signaling cascade. One of the possible therapeutic strategies also concerns immunotherapy. In fact, mutated KRAS tumors, in particular adenocarcinomas with high TMB and related to cigarette smoking, seem to have immunosuppressive activity and are able to induce the production of regulatory T cells. ERBB2/3, Erb-b receptor tyrosine kinase; IGF1R, insulin-like growth factor receptor; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; FGF2, fibroblast growth factor 2; FGFR, FGF receptor; FGFRL, FGFR-like; AXL, anexelekto; PLCG1, phospholipase C gamma 1; CDK, cyclin-dependent kinase; mTOR, mammalian target of rapamycin; KEAP1, Kelch-like ECH-associated protein 1; NFE2L2, nuclear factor, erythroid 2-like 2; NRF2, nuclear factor erythroid 2-like 2; sMAF, small musculoaponeurotic fibrosarcoma; RTKs, receptor tyrosine kinases; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand-1; ICI, immune checkpoint inhibitor; KRAS, Kirsten rat sarcoma viral oncogene; SOS1, son of sevenless homolog 1; SHP2, src homology region 2 domain phosphatase; GDP, guanosine diphosphate; GTP, guanosine triphosphate; RAF, rapidly accelerated fibrosarcoma; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PARP, poly (ADP-ribose) polymerases; RhoA, ras homolog gene family, member A; NF-κB, nuclear factor κB; MET, mesenchymal-epithelial transition; RAS, rat sarcoma viral oncogene homolog; EMT, epithelial-to-mesenchymal transition; TMB, tumor mutational burden.
Figure 3 Novel therapeutic strategies for KRAS-mutant resistant to KRAS G12C inhibitors. Mechanisms of resistance to KRAS G12C inhibitors include compensatory activation of RTKs such as ERBB2/3, FGFR1, AXL and MET. This can lead to SHP2 phosphorylation, which is required for ERK activation through RAS modulation. Another mechanism can be the EMT. The onset of these resistance mechanisms leads to the development of alternative therapeutic strategies. The figure highlights the possibility of combine drugs active on different levels of the cellular signaling cascade. One of the possible therapeutic strategies also concerns immunotherapy. In fact, mutated KRAS tumors, in particular adenocarcinomas with high TMB and related to cigarette smoking, seem to have immunosuppressive activity and are able to induce the production of regulatory T cells. ERBB2/3, Erb-b receptor tyrosine kinase; IGF1R, insulin-like growth factor receptor; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; FGF2, fibroblast growth factor 2; FGFR, FGF receptor; FGFRL, FGFR-like; AXL, anexelekto; PLCG1, phospholipase C gamma 1; CDK, cyclin-dependent kinase; mTOR, mammalian target of rapamycin; KEAP1, Kelch-like ECH-associated protein 1; NFE2L2, nuclear factor, erythroid 2-like 2; NRF2, nuclear factor erythroid 2-like 2; sMAF, small musculoaponeurotic fibrosarcoma; RTKs, receptor tyrosine kinases; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand-1; ICI, immune checkpoint inhibitor; KRAS, Kirsten rat sarcoma viral oncogene; SOS1, son of sevenless homolog 1; SHP2, src homology region 2 domain phosphatase; GDP, guanosine diphosphate; GTP, guanosine triphosphate; RAF, rapidly accelerated fibrosarcoma; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PARP, poly (ADP-ribose) polymerases; RhoA, ras homolog gene family, member A; NF-κB, nuclear factor κB; MET, mesenchymal-epithelial transition; RAS, rat sarcoma viral oncogene homolog; EMT, epithelial-to-mesenchymal transition; TMB, tumor mutational burden.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 124 references

Cited by

See all 76

Metadata

Authors
Santarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R.
Affiliations
  • University of Messina (IT)
  • Amsterdam University Medical Centers (NL)
  • Instituto Oncológico Dr. Rosell (ES)
Corresponding author
Rosell, Rafael
Venue
Translational Lung Cancer Research
Published
2023-02
Volume
12
Issue
2
Pages
346-368
ISSN
  • 2218-6751 (ISSN-L)
  • 2226-4477
OpenAlex
W4321458456
Cited by
65
References
122
Citations by year
2026: 20 · 2025: 24 · 2024: 10 · 2023: 11
FWCI
3.01
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Translational Lung Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, sotorasib, adagrasib, acquired drug resistance, synthetic lethality, combination therapy with immunotherapy, targeted therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review. https://app.cochat.ai/papers/10.21037/tlcr-22-639
The paper
Santarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023). Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review. Translational Lung Cancer Research. https://doi.org/10.21037/tlcr-22-639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.